A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study.

BACKGROUND: Proteasome inhibitors and mammalian target of rapamycin inhibitors each have activity in various B-cell malignancies and affect distinct cellular pathways. Their combination has demonstrated synergy in vitro and in mouse models. METHODS: The authors conducted a single-arm, phase 2 trial of combined temsirolimus and bortezomib in patients with relapsed and refractory B-cell non-Hodgkin lymphoma (NHL) using a dosing scheme that was previously tested in multiple myeloma. The patients received bortezomib and temsirolimus weekly on days 1, 8, 15, and 22 of a 35-day cycle. RESULTS: Of 39 patients who received treatment, 3 achieved a complete response (7.7%; 95% confidence interval [CI], 1.6%-21%), and 9 had a partial response (PR) (23%; 95% CI, 11%-39%). Thus, the overall response rate (12 of 39 patients) was 31% (95% CI, 17%-48%), and the median progression-free survival was 4.7 months (95% CI, 2.1-7.8 months; 2 months for patients with diffuse large B-cell lymphoma [n = 18], 7.5 months for those with mantle cell lymphoma [n = 7], and 16.5 months for those with follicular lymphoma [n = 9]). Two extensively treated patients with diffuse large B-cell lymphoma achieved a complete response. There were no unexpected toxicities from the combination. CONCLUSIONS: The current results demonstrate that the combination of a mammalian target of rapamycin inhibitor and a proteasome inhibitor is safe and has activity in patients with heavily pretreated B-cell NHL. Further studies with this combination are warranted in specific subtypes of NHL.

Knowledge gained after a brief CME module on breast cancer diagnosis.

BACKGROUND: In developing countries, continuing medical education (CME) is lacking and physicians' knowledge of cancer control may also be lacking. METHOD: We evaluated knowledge of 144 primary care physicians in Egypt and 50 in Tunisia regarding breast cancer (BC) and inflammatory BC (IBC) in particular. We invited the physicians to pretesting, presentation of an educational module, and post-testing. RESULTS: We found significant improvement in knowledge about risk factors for IBC and BC, importance of early detection and clinical examination, and referral of IBC cases. The variables that were independently associated with improved BC knowledge, were rural practice location, being a female physician, and greater numbers of BC patients seen in the last year. CONCLUSION. We developed and evaluated a CME module to improve BC diagnostic knowledge of primary care physicians in developing countries. The evaluation showed that physicians most lacking in this knowledge had the greatest gains. With the anticipated adoption of this module in Egypt and Tunisia, we expect to see more appropriate referrals to cancer centers. These results could guide future oncology CME for physicians in developing countries.